Life without COX 2 inhibitors: risks and benefits are determined by dose and potency

Comment

Enrique J Sánchez-Delgado. BMJ. 2006.

. 2006 Jun 17;332(7555):1451-2.

doi: 10.1136/bmj.332.7555.1451-b.

No abstract available

Figures

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
Hippisley-Cox J, Coupland C, Logan R. Hippisley-Cox J, et al. BMJ. 2005 Dec 3;331(7528):1310-6. doi: 10.1136/bmj.331.7528.1310. BMJ. 2005. PMID: 16322018 Free PMC article.
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Kearney PM, et al. BMJ. 2006 Jun 3;332(7553):1302-8. doi: 10.1136/bmj.332.7553.1302. BMJ. 2006. PMID: 16740558 Free PMC article.

1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332: 1302-8. (3 June.) - PMC - PubMed
1. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control study. BMJ 2005;331: 1310-16. - PMC - PubMed
1. Transparenz-Telegramm. Berlin: Arzneimittel-Verlags-GmbH, 1987: 719.
1. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330: 1366. - PMC - PubMed
1. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112: 759-70. - PubMed